Stay Ahead of Wall Street. Find out what is happening to AC Immune SA (NASDAQ:ACIU) stock today? Its price is jumping 0.27 points, trading at $5.22 levels, and is up 5.45% from its previous close of $4.95. The shares seem to have an active trading volume day with a reported 135300 contracts so far this session. ACIU shares had a relatively better volume day versus average trading capacity of 257.37 thousand shares, but with a 32.65 million float and a -1.2% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ACIU stock indicates that the average analyst price target is $10.08 per share. This means the stock has a potential increase of 93.1% from where the ACIU share price has been trading recently which is between $4.92 and $5.05. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $3.98.
The shorts are running away from AC Immune SA (ACIU) stock. The latest set of short interest data was released on 15 May 2019, and the numbers show a drop in short interest in ACIU shares. While short interest still represents only 1.76% of ACIU’s float, the number of shares shorted have fallen by -8999. The number of shares shorted fell to 575503 shares, down from 584502 shares during the preceding fortnight. With average daily trading volumes at 168632 shares, days to cover decreased to about 4.520755 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates” and dated May 15, 2019.
During the recent trading session for AC Immune SA (NASDAQ:ACIU), the company witnessed their stock rise $0.09 over a week and surge $0.1 from the price 20 days ago. When compared to their established 52-week high of $17.4, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 07/23/18. The recent low of $3.25 stood for a -70% since 01/30/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for AC Immune SA, the two-week RSI stands at 56.62. This figure suggests that ACIU stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current ACIU readings is similarly very revealing as it has a stochastic reading of 54.65% at this stage. This figure means that ACIU share price today is being neutral.
Technical chart claims that AC Immune SA (ACIU) would settle between $5.03/share to $5.1/share level. However, if the stock price goes below the $4.9 mark, then the market for AC Immune SA becomes much weaker. If that happens, the stock price might even plunge as low as $4.84 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.01. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at UBS lowered their recommendation on shares of ACIU from Buy to Neutral in their opinion released on February 01. UBS, analysts launched coverage of AC Immune SA (NASDAQ:ACIU) stock with a Buy recommendation, according to their flash note issued to investors on January 04. Analysts at H.C. Wainwright, made their first call for the equity with a Buy recommendation, according to a research note that dated back to April 05.
ACIU equity has an average rating of 1.75, with the figure leaning towards a bullish end. 4 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 3 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 3 analysts rated AC Immune SA (NASDAQ:ACIU) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, ACIU stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 4.09 while for the average stock in the same group, the multiple is 43.05. AC Immune SA current P/E ratio of 15.45 means it is trading at a discount against its industry’s 102.72. In the past 5 years, this ratio for the stock has been fluctuating between 0 and 0.
AC Immune SA (ACIU)’s current-quarter revenues are projected to climb by nearly 318.23% to hit $8.49 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 1344.25% from $7.36 million to a noteworthy $106300. At the other end of the current quarter income statement, AC Immune SA is expected to see its adjusted earnings surge by roughly 25% to hit $-0.15 per share. For the fiscal year, ACIU’s earnings are projected to climb by roughly 255.13% to hit $1.21 per share.